Oliveira LG, Carneiro MLRG, Souza MPGD, Souza CGD, Moraes FBD, Camargo FLD. Osteoporosis Drug Treatment Update.
Rev Bras Ortop 2021;
56:550-557. [PMID:
34733425 PMCID:
PMC8558937 DOI:
10.1055/s-0040-1714219]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Accepted: 04/15/2020] [Indexed: 10/28/2022] Open
Abstract
The Brazilian population is aging and the prevalence of chronic degenerative diseases, including osteoporosis, is increasing. The diagnosis and treatment of osteoporosis have made significant advances in the last decade. The orthopedist and traumatologist can no longer be detained only in the surgical treatment of osteoporotic fracture. It is extremely important that we know: 1) what risk factors to evaluate, and the Fracture Risk Assesment Tool (FRAX) can be used; 2) which complementary tests should be requested, such as densitometry, radiography of the spine and pelvis, blood and urine tests, and even bone biopsy; 3) which supplements to use, such as calcium and magnesium, vitamins D and K; 4) which medications to prescribe, antiresorptives or trainers, therapeutic windows and adverse events.
Collapse